RESUMO
BACKGROUND: Bisphosphonates are the mainstay of osteoporosis treatment, but their use for patients with esophageal varices has been avoided due to the risk of esophagitis, which may cause variceal bleeding. Since most clinical trials assessing osteoporosis treatment last 2-3 years, this study aimed to evaluate a 2-year risedronate treatment for patients with esophageal varices and liver cirrhosis. METHODS: The study received Institutional Review Board approval, and the sample was divided into two groups according to bone mineral density (BMD). Cirrhosis severity and endoscopic findings at baseline were similar between the groups. The intervention group had 51 patients with osteoporosis, who received oral risedronate 35 mg weekly plus calcium and vitamin D supplements. The control group had 51 patients with osteopenia, receiving only the supplements. Scheduled esophagogastroduodenoscopies and BMD measurements were carried out. RESULTS: The adjusted esophagitis risk was higher in the intervention group; however, none of the subjects had digestive bleeding. Lumbar spine BMD increased in the intervention group (- 3.06 ± 0.71 to - 2.33 ± 0.90; p < 0.001) and in the control group (- 1.38 ± 0.77 to - 1.10 ± 1.05; p = 0.012). Femoral neck BMD did not change in the intervention group (- 1.64 ± 0.91 to - 1.71 ± 0.95; p = 0.220), but tended to decrease in the control group (- 1.00 ± 0.74 to - 1.09 ± 0.82; p = 0.053). CONCLUSION: Oral risedronate was effective and did not cause gastrointestinal bleeding in cirrhotic patients with esophageal varices under endoscopic surveillance.
Assuntos
Conservadores da Densidade Óssea , Varizes Esofágicas e Gástricas , Esofagite , Osteoporose , Humanos , Ácido Risedrônico/uso terapêutico , Varizes Esofágicas e Gástricas/complicações , Conservadores da Densidade Óssea/uso terapêutico , Conservadores da Densidade Óssea/efeitos adversos , Hemorragia Gastrointestinal/complicações , Osteoporose/complicações , Osteoporose/tratamento farmacológico , Osteoporose/induzido quimicamente , Densidade Óssea , Cirrose Hepática/complicações , Cirrose Hepática/tratamento farmacológico , Esofagite/induzido quimicamente , Esofagite/complicações , Esofagite/tratamento farmacológicoRESUMO
Despite the high prevalence of osteoporosis in liver cirrhosis, the indication of bisphosphonates for patients with esophageal varices has been avoided due to risk of digestive mucosal damage. Therefore, this study aimed to evaluate the safety profile of risedronate treatment for patients with osteoporosis, liver cirrhosis and esophageal varices with low risk of bleeding. A total of 120 patients were allocated into two groups according to their bone mineral density measured by dual-energy X-ray absorptiometry. In the intervention group, 57 subjects with osteoporosis received oral risedronate at 35 mg weekly plus daily calcium and vitamin D supplementation. In the control group, 63 subjects with osteopenia received only calcium and vitamin D. The groups received the treatment for one year and underwent surveillance endoscopies at six and 12 months, as well as a control dual-energy X-ray absorptiometry after a 12-month follow-up. The study received Institutional Review Board approval. The groups had not only comparable Model for End-stage Liver Disease score and esophageal varices degree, but also similar incidence of digestive adverse effects. A significant improvement was achieved in the intervention group in the lumbar spine T score (p < 0.001). The results suggest that risedronate may be safely used in liver cirrhosis and esophageal varices with low bleeding risk under endoscopic surveillance, thus allowing bone mass recovery.
Assuntos
Varizes Esofágicas e Gástricas/tratamento farmacológico , Cirrose Hepática/tratamento farmacológico , Osteoporose/tratamento farmacológico , Ácido Risedrônico/administração & dosagem , Absorciometria de Fóton , Adulto , Idoso , Cálcio/administração & dosagem , Cálcio/efeitos adversos , Varizes Esofágicas e Gástricas/complicações , Varizes Esofágicas e Gástricas/patologia , Feminino , Seguimentos , Humanos , Cirrose Hepática/complicações , Cirrose Hepática/patologia , Masculino , Pessoa de Meia-Idade , Osteoporose/etiologia , Osteoporose/patologia , Estudos Prospectivos , Ácido Risedrônico/efeitos adversos , Vitamina D/administração & dosagem , Vitamina D/efeitos adversosRESUMO
Branched-chain amino acids increase the brain perfusion of patients with hepatic encephalopathy (HE), but the amino acid and the mechanisms involved are still unknown. This study compared brain perfusion and clinical improvement during leucine or isoleucine supplementation. After randomization, 27 subjects with cirrhosis and HE received leucine or isoleucine supplements for one year. Brain single Photon Emission Computed Tomography (SPECT) and dynamic brain scintigraphy (DBS) were performed pretreatment and at 1, 8 and 12â¯months of supplementation. Brain perfusion was increased only in the isoleucine group at 8â¯months of treatment by both SPECT and DBS (pâ¯<â¯0.001 and pâ¯=â¯0.05, respectively) and by SPECT at the 12th month (pâ¯<â¯0.05). This was associated with hepatic encephalopathy improvement at 8 and 12â¯months (pâ¯=â¯0.008 and 0.004, respectively), which was not observed in the leucine group (pâ¯=â¯0.313 and 0.055, respectively). Isoleucine supplementation achieved a better impact on brain perfusion restoration in HE.